NCT03884647 - DELPHI in Subjects at Risk for Stroke and Dementia | Biotech Hunter

Enrollment

335

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

May 6, 2022

Study Completion Date

May 6, 2022

Conditions

StrokeHypertensionDiabete MellitusDyslipidemiasSleep DisorderSmokingOverweight and ObesityFamilial Alzheimer DiseaseAtrial FibrillationCardiac DiseaseCognitive ImpairmentTransient Ischemic Attack

Interventions

DEVICE

DELPhI system

DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.

Trial Locations (4)

30328

Neurotrials Research, Atlanta

45212

Clinical Research Center CTI, Norwood

94598

Diablo Clinical Research Inc., Walnut Creek

6492601

Sourasky Tel-Aviv Medical Center, Tel Aviv

All Listed Sponsors

lead

QuantalX Neuroscience

INDUSTRY